The historical rank and industry rank for Bafna Pharmaceuticals's OCF Margin % or its related term are showing as below:
NSE:BAFNAPH'
s OCF Margin % Range Over the Past 10 Years
Min: -80.68 Med: 1.42 Max: 15.18
Current: 10.21
During the past 13 years, the highest OCF Margin % of Bafna Pharmaceuticals was 15.18%. The lowest was -80.68%. And the median was 1.42%.
NSE:BAFNAPH's OCF Margin % is ranked better than 51.2% of 959
companies
in the Drug Manufacturers industry
Industry Median: 9.95
vs NSE:BAFNAPH: 10.21
Bafna Pharmaceuticals OCF Margin % Related Terms
Bafna Pharmaceuticals OCF Margin % Historical Data
* Premium members only.
The historical data trend for Bafna Pharmaceuticals's OCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Bafna Pharmaceuticals's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bafna Pharmaceuticals OCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Bafna Pharmaceuticals's OCF Margin % distribution charts can be found below:
* The bar in red indicates where Bafna Pharmaceuticals's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bafna Pharmaceuticals (NSE:BAFNAPH) has a OCF Margin % of 0.00% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Bafna Pharmaceuticals and its competitors. According to the industry distribution chart, Bafna Pharmaceuticals ranks #468 out of 959 companies in the Drug Manufacturers industry, placing it in the top 48.8%.
Is Bafna Pharmaceuticals' OCF Margin % too high?
Bafna Pharmaceuticals' current OCF Margin % is 0.00%. Based on the distribution chart, Bafna Pharmaceuticals ranks #468 out of 959 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Bafna Pharmaceuticals has a GF Score™ of 59/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Bafna Pharmaceuticals' OCF Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Bafna Pharmaceuticals ranks #468 out of 959 companies for OCF Margin %. This puts Bafna Pharmaceuticals in the upper half of its industry. The industry median OCF Margin % is 9.95. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Drug Manufacturers company?
The median OCF Margin % among Drug Manufacturers companies is 9.95, based on 959 companies in the industry. Companies in the top quartile (top 25%) have a OCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Bafna Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median OCF Margin % is 9.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bafna Pharmaceuticals's current OCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bafna Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Bafna Pharmaceuticals (NSE:BAFNAPH) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹90.54, compared to a current price of ₹194.68 — trading 115% above its estimated fair value. The current OCF Margin % is 0.00%. Bafna Pharmaceuticals' overall GF Score™ is 59/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Bafna Pharmaceuticals (NSE:BAFNAPH), the current OCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bafna Pharmaceuticals (NSE:BAFNAPH) Overvalued in 2026?
Based on GuruFocus' analysis, Bafna Pharmaceuticals stock appears to be overvalued.
The current stock price of ₹194.68 is trading 115% above its estimated GF Value™ of ₹90.54.
GuruFocus considers Bafna Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for NSE:BAFNAPH:
OCF Margin %: 0.00%
GF Value™: ₹90.54 vs. price of ₹194.68 (115% above fair value)
No single metric tells the full story. See the NSE:BAFNAPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bafna Pharmaceuticals Ltd is an Indian pharmaceutical company mainly offering Contract Research and Manufacturing (CRAMS), Technology Transfers, Formulation, and Analytical Development services. It is engaged in the business of manufacturing finished pharmaceutical formulations, specializing in non-betalactam solid oral dosage forms, besides other emerging and potential products and forms in various therapeutic areas such as cardiology, lifestyle and potent drugs, and pain management. The company delivers generic pharmaceutical products for the UK, Australia, the EU, and emerging markets. In addition, it has launched its own brands in Sri Lanka, the Philippines, Tanzania, and Nigeria, offering products for some high-demand therapies like diabetes, cardiovascular, and oncology.
59GF Score
Get the complete analysis for NSE:BAFNAPH
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:BAFNAPH has been successfully added to your 
